Literature DB >> 24173089

Hepatitis B virus reactivation associated with ruxolitinib.

Chien-Heng Shen1, Cih-En Hwang, Yi-Yang Chen, Chih-Cheng Chen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24173089     DOI： 10.1007/s00277-013-1936-5

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  11 in total

1.  Reactivation of hepatitis B virus after withdrawal of erlotinib.

Authors:  N Bui; I Wong-Sefidan
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

2.  Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.

Authors:  Norio Komatsu; Keita Kirito; Kazuya Shimoda; Takayuki Ishikawa; Kohshi Ohishi; Kazuma Ohyashiki; Naoto Takahashi; Hikaru Okada; Taro Amagasaki; Toshio Yonezu; Koichi Akashi
Journal:  Int J Hematol       Date:  2016-11-10       Impact factor: 2.490

Review 3.  Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies.

Authors:  Danielle J Smalls; Reagan E Kiger; LeAnn B Norris; Charles L Bennett; Bryan L Love
Journal:  Pharmacotherapy       Date:  2019-11-03       Impact factor: 4.705

Review 4.  Clinical potential of pacritinib in the treatment of myelofibrosis.

Authors:  Ana B Duenas-Perez; Adam J Mead
Journal:  Ther Adv Hematol       Date:  2015-08

Review 5.  Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.

Authors:  Man Fai Law; Rita Ho; Carmen K M Cheung; Lydia H P Tam; Karen Ma; Kent C Y So; Bonaventure Ip; Jacqueline So; Jennifer Lai; Joyce Ng; Tommy H C Tam
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

6.  Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.

Authors:  Palma Manduzio
Journal:  Ther Clin Risk Manag       Date:  2017-02-13       Impact factor: 2.423

Review 7.  Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).

Authors:  Georg Maschmeyer; Julien De Greef; Sibylle C Mellinghoff; Annamaria Nosari; Anne Thiebaut-Bertrand; Anne Bergeron; Tomas Franquet; Nicole M A Blijlevens; Johan A Maertens
Journal:  Leukemia       Date:  2019-01-30       Impact factor: 11.528

Review 8.  Reactivation of hepatitis B virus infection in patients with hematologic disorders.

Authors:  Bo Wang; Ghulam Mufti; Kosh Agarwal
Journal:  Haematologica       Date:  2019-02-07       Impact factor: 9.941

Review 9.  Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis.

Authors:  Giovanni Barosi; Vittorio Rosti; Robert Peter Gale
Journal:  Onco Targets Ther       Date:  2015-05-18       Impact factor: 4.147

10.  A case report of cryptococcal meningitis associated with ruxolitinib.

Authors:  Daisuke Tsukui; Hiroaki Fujita; Keisuke Suzuki; Koichi Hirata
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.